Seeking Alpha

Editors' Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.

Cel-Sci (CVM) is a lead investigational immunotherapy company which is developing a groundbreaking technology to treat head and neck cancer, as well as ways to enhance the body's immune system capability to fight bacterial, viral, and parasitic infections. It's a $65 million sized micro-cap listed on the AMEX. Just 2 weeks ago, a remarkable insider transaction took place:

The CEO doubled his position by buying 300000 shares (!) directly in the open market - not an option transaction - at a price...

Only subscribers can access this article, which is part of the PRO research library covering 3,741 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: